ACS
AZN icon

Archford Capital Strategies’s AstraZeneca AZN Stock Holding History

Archford Capital Strategies’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$498K Buy
+2,652
New +$499K 0.05% 244
2026
Q1 		– Sell
-2,705
Closed -$497K – 345
2025
Q4 		$497K Hold
2,705
– – 0.06% 233
2025
Q3 		$415K Sell
2,705
-4
-0.1% -$605 0.05% 241
2025
Q2 		$379K Buy
2,709
+2
+0.1% +$280 0.05% 246
2025
Q1 		$398K Buy
2,707
+6
+0.2% +$868 0.06% 219
2024
Q4 		$354K Sell
2,701
-3
-0.1% -$420 0.05% 214
2024
Q3 		$422K Sell
2,704
-626
-19% -$101K 0.06% 187
2024
Q2 		$519K Hold
3,330
– – 0.08% 177
2024
Q1 		$451K Sell
3,330
-151
-4% -$20K 0.08% 185
2023
Q4 		$469K Sell
3,481
-616
-15% -$80.1K 0.09% 175
2023
Q3 		$555K Sell
4,097
-796
-16% -$109K 0.11% 183
2023
Q2 		$674K Buy
4,893
+1,113
+29% +$164K 0.13% 168
2023
Q1 		$545K Sell
3,780
-261
-6% -$35.1K 0.11% 193
2022
Q4 		$548K Hold
4,041
– – 0.13% 183
2022
Q3 		$443K Sell
4,041
-39
-1% -$4.95K 0.11% 193
2022
Q2 		$539K Buy
+4,080
New +$535K 0.14% 171
2022
Q1 		– Sell
-4,197
Closed -$489K – 283
2021
Q4 		$489K Sell
4,197
-152
-3% -$17.9K 0.11% 189
2021
Q3 		$522K Buy
4,349
+2
+0% +$233 0.12% 183
2021
Q2 		$521K Sell
4,347
-633
-13% -$69.4K 0.13% 173
2021
Q1 		$506K Sell
4,980
-19,152
-79% -$1.93M 0.13% 168
2020
Q4 		$2.46M Buy
24,132
+19
+0.1% +$2.01K 0.56% 47
2020
Q3 		$2.64M Sell
24,113
-161
-0.7% -$17.9K 0.71% 35
2020
Q2 		$2.57M Sell
24,274
-33
-0.1% -$3.41K 0.76% 28
2020
Q1 		$2.17M Buy
24,307
+307
+1% +$28.9K 0.85% 27
2019
Q4 		$2.39M Sell
24,000
-2,581
-10% -$243K 0.83% 32
2019
Q3 		$2.37M Sell
26,581
-421
-2% -$36.5K 0.88% 26
2019
Q2 		$2.23M Sell
27,002
-2,229
-8% -$175K 0.81% 28
2019
Q1 		$2.36M Sell
29,231
-741
-2% -$58.4K 0.87% 26
2018
Q4 		$2.28M Buy
29,972
+35
+0.1% +$2.73K 0.91% 26
2018
Q3 		$2.37M Sell
29,937
-3,709
-11% -$281K 0.86% 24
2018
Q2 		$2.36M Sell
33,646
-3,247
-9% -$234K 0.83% 23
2018
Q1 		$2.56M Buy
36,893
+23,488
+175% +$1.63M 1.07% 28
2017
Q4 		$930K Sell
13,405
-23,991
-64% -$1.62M 0.35% 93
2017
Q3 		$2.53M Buy
37,396
+149
+0.4% +$9.41K 0.95% 26
2017
Q2 		$2.54M Buy
37,247
+405
+1% +$26.4K 1% 25
2017
Q1 		$2.3M Buy
+36,842
New +$2.14M 0.87% 26
2016
Q4 		– Sell
-35,213
Closed -$2.31M – 644
2016
Q3 		$2.31M Buy
35,213
+24,693
+235% +$1.61M 0.95% 23
2016
Q2 		$635K Sell
10,520
-21,118
-67% -$1.23M 0.33% 99
2016
Q1 		$1.78M Buy
31,638
+958
+3% +$57.6K 0.85% 33
2015
Q4 		$2.16M Buy
30,680
+26,002
+556% +$1.7M 0.98% 22
2015
Q3 		$298K Buy
4,678
+9
+0.2% +$592 0.22% 95
2015
Q2 		$297K Sell
4,669
-842
-15% -$57.6K 0.21% 103
2015
Q1 		$377K Buy
5,511
+1,517
+38% +$105K 0.26% 95
2014
Q4 		$281K Buy
+3,994
New +$286K 0.21% 107

Other funds holding AZN

RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
CDDEC
Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
BTCPP
Border to Coast Pensions Partnership Leeds, United Kingdom $6.78B AUM 31.6% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
ISS
Intesa Sanpaolo SpA. Turin, Italy $2.92B AUM
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Archford Capital Strategies's AZN Position: Q2 2026 in Review

Archford Capital Strategies opened a new position in AstraZeneca (AZN) in Q2 2026: 2,652 shares worth $498K. The stake represents 0.05% of the portfolio and ranks #244 among its holdings. This is a return to the name: Archford Capital Strategies previously reported a position in AZN as recently as Q4 2025.

Archford Capital Strategies first reported a position in AZN in Q4 2014 and has held it in 44 quarters since. The position peaked at $2.64M in Q3 2020. 655 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Archford Capital Strategies held 2,652 shares of AstraZeneca worth $498K as of Q2 2026.
  • AstraZeneca was a new Archford Capital Strategies position in Q2 2026.
  • AstraZeneca made up 0.05% of Archford Capital Strategies's portfolio in Q2 2026, its #244 holding.
  • Archford Capital Strategies first reported a position in AstraZeneca in Q4 2014 and has held it in 44 quarters since.
  • Archford Capital Strategies's AstraZeneca position peaked at $2.64M in Q3 2020.
  • 655 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Archford Capital Strategies's 13F filing for Q2 2026, filed 17 Jul 2026.